Cargando…

SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma

BACKGROUND: Gastric carcinoma and primary gastric lymphoma (PGL) are the two most common malignancies in stomach. The purpose of this study was to screen and validate a biomarker of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) for distinguishing advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Liping, Li, Hongming, Wang, Hui, Xu, Baixuan, Fan, Yong, Tian, Jiahe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514221/
https://www.ncbi.nlm.nih.gov/pubmed/23226547
http://dx.doi.org/10.1371/journal.pone.0050914
_version_ 1782251992348884992
author Fu, Liping
Li, Hongming
Wang, Hui
Xu, Baixuan
Fan, Yong
Tian, Jiahe
author_facet Fu, Liping
Li, Hongming
Wang, Hui
Xu, Baixuan
Fan, Yong
Tian, Jiahe
author_sort Fu, Liping
collection PubMed
description BACKGROUND: Gastric carcinoma and primary gastric lymphoma (PGL) are the two most common malignancies in stomach. The purpose of this study was to screen and validate a biomarker of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) for distinguishing advanced gastric carcinoma (AGC) from PGL for clinical applications. METHODOLOGY/PRINCIPAL FINDINGS: We reviewed PET/CT scans collected from January 2008 to April 2012 of 69 AGC and 38 PGL (14 low-grade mucosa-associated lymphoid tissue [MALT], 24 non-MALT aggressive non-Hodgkin lymphoma [ANHL]) with a focus on FDG intensity (maximum standardized uptake value [SUVmax]) of primary lesions and its CT-detected abnormalities, including maximal gastrointestinal wall thickness (THKmax) and mucosal ulcerations. Gastric FDG uptake was found in 69 (100%) patients with AGC and 36 (95%, 12 MALT vs. 24 ANHL)with PGL. The presence of CT-detected abnormalities of AGC and PGL were 97% (67/69) and 89% (12 MALT vs. 22 ANHL), respectively. After controlling for THKmax, SUVmax was higher with ANHL than AGC (17.10±8.08 vs. 9.65±5.24, p<0.05) and MALT (6.20±3.60, p<0.05). THKmax did not differ among MALT, ANHL and AGC. Mucosal ulceration was more common with AGC (n = 9) than PGL (n = 2),but the difference was not statistically significant (p>0.05). Cross-validation analysis showed that for distinguishing ANHL from AGC, the classifier with SUVmax as a feature achieved a correct classification rate of 81% with thresholds 13.40±1.12 and the classifier with SUVmax/THKmax as a feature achieved a correct classification rate of 83% with thresholds 7.51±0.63. CONCLUSIONS/SIGNIFICANCE: SUVmax/THKmax may be as a promising biomarker of FDG-PET/CT for distinguishing ANHL from AGC. Structural CT abnormalities alone may not be reliable but can help with PET assessment of gastric malignancies. (18)F-FDG PET/CT have potential for distinguishing AGC from PGL at the individual level.
format Online
Article
Text
id pubmed-3514221
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-35142212012-12-05 SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma Fu, Liping Li, Hongming Wang, Hui Xu, Baixuan Fan, Yong Tian, Jiahe PLoS One Research Article BACKGROUND: Gastric carcinoma and primary gastric lymphoma (PGL) are the two most common malignancies in stomach. The purpose of this study was to screen and validate a biomarker of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) for distinguishing advanced gastric carcinoma (AGC) from PGL for clinical applications. METHODOLOGY/PRINCIPAL FINDINGS: We reviewed PET/CT scans collected from January 2008 to April 2012 of 69 AGC and 38 PGL (14 low-grade mucosa-associated lymphoid tissue [MALT], 24 non-MALT aggressive non-Hodgkin lymphoma [ANHL]) with a focus on FDG intensity (maximum standardized uptake value [SUVmax]) of primary lesions and its CT-detected abnormalities, including maximal gastrointestinal wall thickness (THKmax) and mucosal ulcerations. Gastric FDG uptake was found in 69 (100%) patients with AGC and 36 (95%, 12 MALT vs. 24 ANHL)with PGL. The presence of CT-detected abnormalities of AGC and PGL were 97% (67/69) and 89% (12 MALT vs. 22 ANHL), respectively. After controlling for THKmax, SUVmax was higher with ANHL than AGC (17.10±8.08 vs. 9.65±5.24, p<0.05) and MALT (6.20±3.60, p<0.05). THKmax did not differ among MALT, ANHL and AGC. Mucosal ulceration was more common with AGC (n = 9) than PGL (n = 2),but the difference was not statistically significant (p>0.05). Cross-validation analysis showed that for distinguishing ANHL from AGC, the classifier with SUVmax as a feature achieved a correct classification rate of 81% with thresholds 13.40±1.12 and the classifier with SUVmax/THKmax as a feature achieved a correct classification rate of 83% with thresholds 7.51±0.63. CONCLUSIONS/SIGNIFICANCE: SUVmax/THKmax may be as a promising biomarker of FDG-PET/CT for distinguishing ANHL from AGC. Structural CT abnormalities alone may not be reliable but can help with PET assessment of gastric malignancies. (18)F-FDG PET/CT have potential for distinguishing AGC from PGL at the individual level. Public Library of Science 2012-12-04 /pmc/articles/PMC3514221/ /pubmed/23226547 http://dx.doi.org/10.1371/journal.pone.0050914 Text en © 2012 Fu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Fu, Liping
Li, Hongming
Wang, Hui
Xu, Baixuan
Fan, Yong
Tian, Jiahe
SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma
title SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma
title_full SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma
title_fullStr SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma
title_full_unstemmed SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma
title_short SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma
title_sort suvmax/thkmax as a biomarker for distinguishing advanced gastric carcinoma from primary gastric lymphoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514221/
https://www.ncbi.nlm.nih.gov/pubmed/23226547
http://dx.doi.org/10.1371/journal.pone.0050914
work_keys_str_mv AT fuliping suvmaxthkmaxasabiomarkerfordistinguishingadvancedgastriccarcinomafromprimarygastriclymphoma
AT lihongming suvmaxthkmaxasabiomarkerfordistinguishingadvancedgastriccarcinomafromprimarygastriclymphoma
AT wanghui suvmaxthkmaxasabiomarkerfordistinguishingadvancedgastriccarcinomafromprimarygastriclymphoma
AT xubaixuan suvmaxthkmaxasabiomarkerfordistinguishingadvancedgastriccarcinomafromprimarygastriclymphoma
AT fanyong suvmaxthkmaxasabiomarkerfordistinguishingadvancedgastriccarcinomafromprimarygastriclymphoma
AT tianjiahe suvmaxthkmaxasabiomarkerfordistinguishingadvancedgastriccarcinomafromprimarygastriclymphoma